A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
一项针对实体瘤的血管生成抑制剂 SU5416（semaxanib）的 I 期研究，纳入了动态对比 MR 药效学终点
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6602797
O'Donnell A, Padhani A, Hayes C, Kakkar A J, Leach M, Trigo J M, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I
